Showing 1261-1270 of 1484 results for "".
- Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 US and European Patentshttps://modernod.com/news/azura-ophthalmics-expands-broad-intellectual-property-portfolio-to-12-us-and-european-patents/2481182/Azura Ophthalmics announced the company’s US 11,459,351 patent (the ‘351 patent) was granted by the US Patent and Trademark Office. This patent strengthens the company’s extensive portfolio protecting its use of dual-action keratolytic drug conjugates in developme
- Pixium Vision Announces Regulatory Approval of Remote Rehabilitation System for Patients in Clinical Trialshttps://modernod.com/news/pixium-vision-announces-regulatory-approval-of-remote-rehabilitation-system-for-patients-in-clinical-trials/2481010/Pixium Vision announced the approval of the remote rehabilitation system for patients enrolled in the PRIMAvera pivotal trial and the French Feasibility Study in atrophic dry age-related macular degeneration (AMD). The approval was granted by the Ethics Commitee and the Regulatory Autho
- Second Sight Medical Products Announces Year 4 NIH Funding of its Orion Studyhttps://modernod.com/news/second-sight-medical-products-announces-year-4-nih-funding-of-its-orion-study/2480982/Second Sight Medical Products announced that the company received notice from the National Institutes of Health (NIH) of the release of year 4 funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (Orion Trial), grant 5UH3NS103442. The NIH released&n
- Apellis Announces FDA Acceptance and Priority Review of the NDA for Pegcetacoplan for the Treatment of Geographic Atrophyhttps://modernod.com/news/apellis-announces-fda-acceptance-and-priority-review-of-the-nda-for-pegcetacoplan-for-the-treatment-of-geographic-atrophy/2480973/Apellis Pharmaceuticals announced that the FDA has accepted and granted Priority Review designation for the intravitreal pegcetacoplan new drug application (NDA). Pegcetacoplan is an investigational, targeted C3 therapy for the treatment of geographic atrophy (GA) secondary to age-relat
- Novartis Receives European Commission Approval of Beovu for Diabetic Macular Edema (DME)https://modernod.com/news/novartis-announces-european-commission-approval-of-beovu-for-diabetic-macular-edema-dme/2480740/Novartis announced that the European Commission (EC) has approved Beovu (brolucizumab) 6 mg for the treatment of visual impairment due to diabetic macular edema (DME). Today’s approval in DME represents the second indication for Beovu granted by the EC, which was first approved for the
- Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTEAR100 Neurostimulation Devicehttps://modernod.com/news/olympic-ophthalmics-announces-fda-clearance-and-availability-of-its-next-generation-itear100-neurostimulation-device-expanded-patent-portfolio-and-further-clinical-studies/2480737/Olympic Ophthalmics announced that the FDA has granted 510(K) clearence for its second-generation iTEAR100 device, a prescription neuromodulation therapy to acutely increase tear production in adult patients over a 30-day period. The second-generation device is a connected device o
- FDA Approves Staar Surgical's EVO Visian Implantable Collamer Lenseshttps://modernod.com/news/staar-surgical-announces-fda-approval-of-evo-visian-implantable-collamer-lenses/2480724/Staar Surgical Company announced that the FDA has granted approval of the EVO/EVO+ Visian Implantable Collamer Lens (EVO) for the correction of myopia and myopia with astigmatism. "Following FDA approval, prospective patients in the U.S. and their doctors may n
- Oculis Announces Licensing Agreement for Neuroprotective Drug Candidate for Glaucoma from Accure Therapeuticshttps://modernod.com/news/oculis-announces-licensing-agreement-for-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/2480683/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina. Under the terms of the agreement, Accure
- Reichert Technologies Celebrates 100 Years of Phoroptorhttps://modernod.com/news/reichert-technologies-celebrates-100-years-of-phoroptor/2480561/Reichert Technologies is celebrating 100 years of the Phoroptor. On January 10, 1922, the United States Patent & Trademark Office granted a registered trademark to the word "Phoroptor" to coincide with its first model release. Ever since, Phoroptor has been synonymous with vision ca
- IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injuryhttps://modernod.com/news/iacta-pharmaceuticals-receives-us-department-of-defense-funding-of-1-million-to-conduct-preclinical-studies-of-ic-800-to-treat-pain-relief-for-eye-injury/2480382/IACTA Pharmaceuticals announced that the U.S. Army Medical Research Acquisition Activity (USAMRAA), a division of the Department of Defense, has granted a $1 million award to the company to fund preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain utilizing